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Abstract
Simple classification approaches for clinical genomic data can often have discrimination power comparable to that of more complex procedures. In this paper we study an
algorithm that has gained traction in practice but has not been thoroughly investigated
in the statistical literature. This method calculates prognostic scores for discrimination
by summing standardized predictors, weighted by the signs of their marginal associations with the outcome. We provide a formal definition of the method and study
theoretical properties that explain why it can achieve surprisingly good discrimination
in clinical genomics. We refer to this method as más-o-menos, because in Spanish
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the phrase “más o menos” means both “plus or minus”, describing the method’s implementation, and “so-so”, describing its non-optimal but still decent discrimination
performance. Through simulations and a comprehensive analysis of gene expression
datasets of ovarian tumors with survival information, we confirm that más-o-menos
can match and even exceed the discrimination power of more established methods,
with a significant advantage in speed, ease of implementation and interpretation, and
reproducibility across clinical and technological settings.
Keywords: gene signatures; clinical genomics; prognostic modeling; risk score

1

Introduction

The successful translation of genomic signatures into clinical settings relies on good discrimination between patient subgroups that should receive diﬀerent clinical management, and on
ease of model implementation and interpretation. Whereas relatively sophisticated methods
such as penalized regression, support vector machines, random forests, bagging and boosting
have received detailed treatments in the statistics and machine learning literature (Hastie
et al., 2005), many practitioners prefer simpler algorithms and prediction models (Hand,
2006). However, the operating characteristics of some of these simpler procedures have not
yet been thoroughly investigated.
In this article we formalize and systematically investigate a family of simple yet robust
classiﬁers for genomic data, where the coeﬃcients of the linear risk score for standardized
covariates are equal to the signs of the univariate associations with the clinical outcome
of interest. In other words, the risk score is equal to number of “bad prognosis” features
minus the number of “good prognosis” features. The procedure can also be preceded by a
feature selection step to exclude irrelevant features from the analysis. We will show that in
some circumstances this method can achieve quite good discrimination performance, comparable to that of more complex procedures. For this reason we refer to this method as
más-o-menos, because in Spanish the phrase “más o menos” means both “plus or minus”,
2
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describing the method’s implementation, and “so-so”, describing its non-optimal but still
decent performance.
Más-o-menos and closely related variants can be found in the top clinical, bioinformatic,
and general science journals (Colman et al., 2010; Dave et al., 2004; Réme et al., 2013;
Bell et al., 2011), and in commercially available prognostic gene signatures, such as the
MyPRS Plus signature for multiple myeloma prognosis (Shaughnessy et al., 2007). Evidence
of the method’s eﬀectiveness crosses disciplines: it has been observed in the credit scoring
literature that large deviations from optimal weights in a linear predictor do not perform
much worse than optimal (Lovie and Lovie, 1986), and in the psychometrics literature that
equally weighting predictors in a linear regression gives nearly the same predictive accuracy
as the least-squares regression coeﬃcients (Wainer, 1976; Laughlin, 1978; Davis-Stober et al.,
2010). It has even been proposed, in a formula-free article, as a practical algorithm that
can be performed in a spreadsheet with the “software and skill sets available to the cancer
biologist” (Hallett et al., 2010).
There is, however, limited theoretical and computational investigation of the basis for
simple average classiﬁers in the statistical genomics literature. Hand (2006) provides some
theoretical arguments to justify equalization of regression coeﬃcients when all covariates
have the same direction of eﬀect with the outcome, and this direction is known a priori.
Hand describes this in terms of the “ﬂat maximum eﬀect”: that in the context of classiﬁers,
often little advantage can be gained in prediction accuracy over very simple models. Simple
averaging has been shown to be useful for reducing variance in gene expression measurements prior to Lasso penalized regression (Park et al., 2007), and the replacement of Lasso
coeﬃcients by their signs has been proposed for summarizing gene pathway activity (Eng
et al., 2013). However to the best of our knowledge, theoretical properties of más-o-menos for
discrimination in high-dimensional data have not been described. Furthermore, situations in
which it is or is not eﬀective have not been discussed, and no systematic comparison relative
to other prediction methods in clinical genomics has been made.
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We aim to provide a formal deﬁnition of más-o-menos, investigate its theoretical properties, provide a systematic assessment relative to more well-established alternative methods,
and establish the pre-conditions for eﬀectiveness of this method. The paper is organized
as follows: we ﬁrst formally deﬁne the method in Section 2. We then study its theoretical
properties for discrimination performance and variability in Section 3, which explain the
results we see in our simulation studies in Section 4. Finally, we show that más-o-menos
out-performs ridge and lasso regression, in terms of both speed and accuracy, for prediction of ovarian cancer prognosis in a meta-analysis of 14 datasets totalling 1,455 patients in
Section 5. We discuss the implications of these ﬁndings in Section 6.

2

The más-o-menos method

Let Xij be a quantitative measurement of the j th gene from the ith subject. The Xij form the
p × 1 covariate vector Xi = (Xi1 , . . . , Xip )T . Covariates could represent various types of genomic information, such as expression levels from microarrays or next-generation sequencing
experiments, or non-genomic data.
The más-o-menos procedure a way to use a patient’s Xi to calculate a linear risk score,
a weighted sum of that patient’s covariate values. The weights are generally estimated from
a training dataset, and diﬀerent methods for calculating linear risk scores result in diﬀerent
weights. Más-o-menos estimates the weights as follows:
1. Perform feature selection, for example using marginal screening (see remark below).
2. Standardize the retained covariates such that (n − 1)−1

∑

(Xij − X̄j )2 = 1, j = 1, . . . , p.

3. Perform univariate regressions, for each Xij , on the outcome to obtain marginal estimates of the regression coeﬃcient α̂j .
4. Let v̂j = sgn(α̂j )/p1/2 , where sgn(c) = 2I(c > 0) − 1 for c ̸= 0 and sgn(c) = 0 for c = 0.
For the j not retained by feature selection, v̂j = 0.
4
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5. The risk score for the ith patient is calculated as XTi v̂, where v̂ = (v̂1 , . . . , v̂p )T .
The factor of p1/2 in the deﬁnition of the v̂j merely serves to ensure the arbitrary scaling
∥v̂∥2 = 1. By changing the regression model used in step (3), más-o-menos can be used with
clinical outcomes of any type, such as continuous, binary, or censored data. The discriminative performance of XTi v̂ can be quantiﬁed using correlation for continuous outcomes, the
area under the receiver operating characteristic curve (AUC) for binary outcomes (Bamber,
1975), or the C-statistic for censored outcomes (Uno et al., 2011).
Remark 1. The feature selection step has been the subject of a great deal of recent research
and a detailed discussion is beyond the scope of this paper. In the remainder of the paper we
perform feature via marginal screening (Fan and Lv, 2008; Fan and Song, 2010; Zhao and Li,
2012) by selecting the Xij with the lowest univariate regression p-values. It has been shown
that under certain conditions, this screening procedure will retain all important covariates
with high probability. We choose the optimal number of variables to retain by maximizing
a cross-validated estimate of discrimination ability, such as the AUC or the C-statistic.
A variety of procedures closely related to más-o-menos have been previously proposed.
These also use marginal regression to identify good and bad prognosis covariates, which are
then used to rank patients by risk. Ranking methods include the t-statistic for diﬀerence in
expression of good vs. bad prognosis genes (Bell et al., 2011; Verhaak and Tamayo, 2013) and
signed averaging of discretized or continuous expression values (Dave et al., 2004; Colman
et al., 2010; Hallett et al., 2010; Kang et al., 2012; Réme et al., 2013). In contrast to these
studies, we provide a more statistical analysis of the properties of más-o-menos.

3

Theoretical properties

In this paper we focus on survival outcomes, because they are typically the most diﬃcult to
deal with and the most clinically relevant. We show that under certain conditions, the máso-menos weights can have fairly high discrimination power along with very low variability.
5
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Let v∗ = (v1∗ , . . . , vp∗ )T be the probability limit of v̂, such that v̂ → v∗ . Since v̂j = sgn(α̂j ),
if α̂j → α0j in probability, then by the continuous mapping theorem vj∗ = sgn(α0j ). Deﬁne
M = {j : α0j ̸= 0} to be the set of covariates marginally associated with Ti , and let s = |M|.
We assume that {j : β0j = 0} ⊆ M, which is crucial for any marginal regression-based
procedure and is commonly made in the marginal screening literature.
Let Ti be the survival time of the ith subject. To measure discrimination in the survival
setting, we use the C-statistic over the follow-up period (0, τ ), deﬁned by Uno et al. (2011)
as
Cτ (β) = P {g(Xi ) > g(Xj ) | Ti < Tj , Ti < τ },
where g(X) is the risk score for a subject with covariate vector X. While in general g can
have any functional form, it is frequently taken to be linear in X. We consider risk scores of
the form g(X) = XT β for β = (β1 , . . . , βp )T . We deﬁne the optimal weight vector to be
β 0 = arg max P (XTi β > XTj β | Ti < Tj , Ti < τ ), ∥β 0 ∥2 = 1,
β

where we have arbitrarily scaled β 0 to have norm 1 because Cτ (β) is invariant to scaling
of β. We will analyze the performance of the más-o-menos estimator v̂ in terms of the
discrimination ability of v∗ relative to that of β 0 , and the variability of v̂ around v∗ .
While the C-statistic is a popular metric for quantifying discrimination, many authors
have recognized that it is not very sensitive. In other words, there are cases where the
diﬀerence in discriminative ability between two competing models must be very large in order
to see a meaningful diﬀerence in their C-statistics. One increasingly popular alternative is
the the Integrated Discrimination Improvement Index (IDI) (Pencina et al., 2008; Uno et al.,
2009). On the other hand, Hilden and Gerds (2013) recently argued that using the IDI is
not always safe. In the absence of a well-accepted alternative, we focus on the C-statistic in
this paper.
To implement más-o-menos in this setting, we will obtain the α̂j by ﬁtting univariate
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Cox models. We choose the Cox model because it is a well-established and well-understood
procedure in clinical research. In addition, the estimators α̂j converge to well-deﬁned α0j
even when the Cox model is not correctly speciﬁed (Struthers and Kalbﬂeisch, 1986; Lin and
Wei, 1989), as is likely to be the case in our marginal regressions. Finally, if the data truly
come from a Cox model, the true parameter vector should maximize Cτ , and should be a
scalar multiple of the optimal β 0 .

3.1

Discrimination performance

By the deﬁnition of Cτ , the discrimination performance of v∗ = (v1∗ , . . . , vp∗ )T depends only
on cor(XTi β 0 , XTi v∗ ). Under certain conditions, this correlation can be fairly high, so the
discrimination performance of the v∗ is not much worse than that of the optimal β 0 .
In particular,
cov(XTi β 0 , XTi v∗ ) =

∑

β0j cov(Xij , Xik vk∗ )

j,k∈M

=

∑

β0j vj∗

j∈M

≥ ρ̄

∑

∑

cov(Xij vj∗ , Xik vk∗ )

k∈M

β0j vj∗ ,

j∈M

where ρ̄ = minj∈M |M|−1

∑
k∈M

cov(Xij vj∗ , Xik vk∗ ). The second equality follows because

vj∗2 = 1 for j ∈ M. Thus XTi v∗ will be highly correlated with XTi β 0 , and will have similar
∑
discriminative ability, under the condition that j∈M β0j vj∗ and ρ̄ have the same sign.
It is not unreasonable to expect these terms to be positive. We ﬁrst consider the term
∑
j∈M

β0j vj∗ . Each β0j quantiﬁes the association between Xij and Ti conditional on all genes

in Xi , while each vj∗ reﬂects its univariate association. If a gene has the same direction of
eﬀect in both the conditional and marginal models, then β0j vj∗ > 0. This is plausible for at
∑
least some genes, and even if it does not hold for all genes j∈M β0j vj∗ can still be positive.
The ρ̄ term is the minimum average correlation between Xij vj∗ and Xik vk∗ for j, k ∈ M.
7
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This will be positive if genes with the same marginal directions of eﬀect tend to be positively
correlated, while genes with diﬀerent marginal directions of eﬀect tend to be negatively
correlated. This is also not unreasonable, as the encoded proteins of conserved co-expressed
gene pairs are likely to be part of the same biological pathway (van Noort et al., 2003). As
before, ρ̄ can be positive even if this correlation condition holds only for some pairs of genes,
as we merely need the average correlation to be positive.

3.2

Variability

An additional appealing feature of más-o-menos is its low variability, which makes it more
robust against overﬁtting and more reproducible across diﬀerent datasets and technologies.
The variability of v̂j is given by



P (α̂j < 0)



P (v̂j =
̸ vj∗ ) =
P (α̂j > 0)




 P (α̂j ̸= 0)

if α0j > 0,
if α0j < 0,
if α0j = 0.

Lin and Wei (1989) showed that α̂j →D N (α0j , σj2 /n) for some α0j and σj2 . This approximation, combined with Mill’s inequality, gives the approximate relation

P (v̂j ̸=

vj∗ )

(
)
2
n
σj
1 α0j
√ exp −
.
2 σj2
n1/2 |α0j | 2π

for α0j ̸= 0, which approaches 0 much faster than var(α̂j ). For large n and/or large |α0j |,
the variability of v̂j will be much closer to zero than the variability of marginal regression.
Thus v̂ is likely to be more robust and less susceptible to overﬁtting, and as a result can
have better out-of-sample discrimination performance.
One diﬃculty arises when α0j = 0. Since α̂j is a continuous estimator, P (α̂j ̸= 0) = 1
for any sample size. In other words, if más-o-menos is used on data where many of the
covariates are not marginally associated with the outcome, it can actually be more variable
8
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than the marginal estimator and may perform worse. This is the reason for the initial feature
selection step, which should remove many unimportant covariates so that there are few j
such that α0j = 0.

4

Simulations

We conducted simulations to compare más-o-menos and three popular analysis methods
that also generate linear risk scores: lasso (Tibshirani, 1996, 1997), ridge regression (Hoerl
and Kennard, 1970; Verweij and Van Houwelingen, 1994), and marginal regression (Emura
∑
et al., 2012), which generates risk scores of the form j Xij α̂j . In several conﬁgurations of
dimensionality, regression parameter sparsity, covariance structure, and correlation strength,
we found that más-o-menos had similar discriminative ability but was signiﬁcantly faster to
implement and execute than lasso and ridge regression.

4.1

Setup

For the lasso and ridge we standardized the covariates to have variance 1. We also included
two negative controls: 1) the single gene with the largest α̂j estimated from the training set,
∑
and 2) randomly generated risk scores j Xij Zj , where the Zj were drawn independently
from a standard normal. We implemented lasso and ridge regression for the Cox model
using the package glmnet (Friedman et al., 2010), selecting the penalty parameter using the
built-in cross-validation function. Marginal Cox regressions can be performed very quickly
with the function rowCoxTests found in the R package survHD (Bernau and Riester, 2012).
To generate a training dataset, on which we ﬁt our regression methods, we generated p×1
covariate vectors Xi and survival times from a Cox model with a p × 1 true parameter vector
β 0 . We let β 0 have s non-zero components all with magnitude s−1/2 , such that ∥β 0 ∥2 = 1.
The ﬁrst s/2 nonzero components were positive and the rest were negative. We generated
censoring times from an independent exponential distribution to give approximately 50%
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censoring. Each simulation contained n = 200 independent observations.
To study the eﬀect of dimensionality, we considered the low-dimensional case of p = 50
and the high-dimensional one of p = 10000. To generate sparse β 0 , we let s = 10, and for
non-sparse β 0 we let s = p. In Section 3.1 we saw that the bias of más-o-menos depends
on the covariance structure of the Xi , so we considered an “easy” structure and a “hard”
structure. In the former, the covariates were divided into two blocks, with Xij positively
correlated within blocks and negatively correlated between blocks. Those Xij with β0j > 0
were assigned to one block, those with β0j < 0 were assigned to the other, and those with
β0j = 0 were assigned equally between the blocks. In the latter, we let cor(Xij , Xik ) > 0 for j
and k both even or both odd, and cor(Xij , Xik ) < 0 otherwise, regardless of the signs of the
corresponding β0j and β0k . We then drew Xi from a multivariate normal with unit marginal
variance. Finally, we considered diﬀerent levels of correlation, with | cor(Xij , Xik )| = 0, 0.3,
or 0.5 for all j and k.
We preceded each procedure, other than the method using the single best gene as the
risk score, with a prescreening step that kept covariates with low marginal Cox regression
p-values. We performed 3-fold cross-validation to choose the optimal number of covariates to
retain: within each fold we implemented the screening step, ﬁt the risk score, and calculated
the C-statistic on the test fold using the method of Uno et al. (2011). We then picked the
optimal number of retained covariates to maximize the average C-statistic across the folds.

4.2

Computation time

We ﬁrst compared computation times for the diﬀerent methods, averaged over 200 simulations. The computations in this paper were run on the Odyssey cluster supported by the
FAS Science Division Research Computing Group at Harvard University.
Table 1 illustrates the speed advantage enjoyed by más-o-menos. Marginal regression
and más-o-menos could be more than 100 times faster than lasso and 15 times faster than
ridge when p = 100. When p = 10000, más-o-menos was still faster by a factor of 10 to 20.
10
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Table 1: Average simulation runtime in seconds
Method p = 100 p = 10000
Lasso 98.7534 637.9471
Ridge 10.5475 337.5248
Marginal 0.7037
28.4332
Más-o-menos 0.8052
52.5774
Single 0.0167
1.6741
Random 0.5401
9.5072

4.3

Discriminative Ability by C-statistics

In addition to being very fast, más-o-menos can nearly match the more complicated procedures in discriminative ability. Performance of all methods is impacted by covariance
structure, sparsity, and magnitude of associations, but in general, más-o-menos kept pace
with lasso, ridge, and marginal regression. Each of these performed better than the single
best gene and the randomly generated negative control.
Figure 1 reports the average out-of-sample C-statistics obtained by the diﬀerent methods.
Conﬁdence intervals represent the empirical 2.5% and 97.5% quantiles. The results clearly
illustrate the importance of the covariance structure. All of the methods except for the
negative control performed better under the easy covariance setting than under the hard
one. The easy covariance satisﬁes the assumptions of the theoretical discussion in Section 3.1:
cor(Xij vj∗ , Ti ) > 0 and cor(Xij vj∗ , Xik vk∗ ) > 0 for all j, k. The diﬃculty of the hard covariance
structure arises from the fact that it is impossible to meet this condition. For example, by
construction, cor(Xi1 , Ti ) > 0 and cor(Xi2 , Ti ) > 0, but cor(Xi1 , Xi2 ) < 0. In other words,
the signs of the β0j and the directions of the covariate correlations are incoherent in the hard
covariance case.
The eﬀect of dimensionality depended on the sparsity and the covariance structure. When
the covariates were independent, higher dimensionality made discrimination harder regardless of sparsity, perhaps because there was no way to borrow information across the covariates. Under the easy covariance structure, high dimensionality was still detrimental under
the sparse setting, perhaps due to the diﬃculty of selecting the important covariates through
11
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Figure 1: Average validation C-statistics of diﬀerent discrimination methods in simulated
data. Más-o-menos results highlighted by red circle.
the prescreening procedure. With a dense β 0 , however, high dimensionality was actually beneﬁcial, perhaps because if the eﬀects of some covariates were by chance incorrectly estimated,
there were many other correlated ones that could be used as surrogates. On the other hand,
with a hard covariance matrix, dimensionality added diﬃculty even in the non-sparse case
because of the incoherence between the β0j and the covariate correlations.
The impact of sparsity depended on the correlation structure. With no correlation,
sparsity allowed for easier discrimination. When correlation was introduced in the easy
covariance setting, sparsity was detrimental to prediction. This might have been due to the
screening step, because univariate screening is liable to retain unimportant covariates simply
because they are correlated with important ones. These incorrectly retained covariates can
degrade performance. In the hard covariance setting, however, sparsity was helpful regardless
of the level of correlation. This may be because in the sparse case, there were fewer important
covariates with which the hard covariance structure could cause diﬃcultly.
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Figure 2: Average correlations of diﬀerent discrimination methods with más-o-menos risk
score in simulated data.

4.4

Similarity of risk scores

The question arises as to whether lasso, ridge, marginal regression, and más-o-menos give
similar risk scores. To address this issue, we report in Figure 2 the average correlations
between the más-o-menos risk score and the scores generated by the other methods. In
general, we see that the results of all methods except for the negative controls are generally
highly correlated. When ρ = 0, ridge and marginal regression were decently correlated with
más-o-menos, though less so in high-dimensions. Lasso was not as highly correlated, perhaps
because of its sparse estimates, but in these situations the discrimination performances of
all methods were very low. Under the easy covariance setting, however, correlations between
all methods except negative controls were close to 1, as they were with a hard covariance
matrix and sparse β 0 . In the most diﬃcult setting, a hard covariance matrix and non-sparse
β 0 , the correlations with más-o-menos returned to the levels when ρ = 0.
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Table 2: Datasets from Ganzfried et al. (2013), 6147 probesets in common
Name Sample size Events Reference
E.MTAB.386
129
73
Bentink et al. (2012)
GSE13876
157
113
Crijns et al. (2009)
GSE14764
41
13
Denkert et al. (2009)
GSE17260
110
46
Yoshihara et al. (2010)
GSE18520
53
41
Mok et al. (2009)
GSE19829.GPL570
28
17
Konstantinopoulos et al. (2010)
GSE19829.GPL8300
42
23
Konstantinopoulos et al. (2010)
GSE26712
185
129
Bonome et al. (2008)
GSE32062.GPL6480
129
60
Yoshihara et al. (2012)
GSE32063
17
10
Yoshihara et al. (2012)
GSE9891
140
72
Tothill et al. (2008)
PMID17290060
59
36
Dressman et al. (2007)
PMID19318476
24
12
Berchuck et al. (2009)
TCGA
452
239
Bell et al. (2011)

5

Discrimination of ovarian cancer outcome

It is of great interest to distinguish between long and shorter-term survivors of ovarian cancer,
so that the higher risk patients can be treated with alternative therapies. Ganzfried et al.
(2013) have compiled and curated an extensive collection of publicly available ovarian cancer
gene expression studies, and have standardized their clinical annotations, probeset identiﬁers,
and microarray preprocessing. We use their datasets to train and validate prognostic scores
for overall survival in a total of 1,445 patients from 14 datasets. This collection is available
as a BioConductor package (Ganzfried et al., 2012).
We focused on patients with late stage, high grade serous tumors with available survival
information, giving us 14 datasets from the Ganzfried et al. (2013) collection to work with
(see Table 2). We limited our analysis to the 6138 probesets found in all 14 studies. We
selected the largest available study (Bell et al., 2011) (“TCGA”) for training, which had
more than twice as many samples than any other single dataset. We standardized probesets
to unit variance in the TCGA training dataset, then applied the scales determined from the
training dataset to each test dataset. As in the simulations, we compared más-o-menos to
lasso, ridge, marginal regression, the single best gene, and a randomly generated negative
14
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control. We used these procedures to estimate risk score weights in the TCGA dataset,
because it had the largest number of events, and we compared the C-statistics achieved by
these diﬀerent scoring systems on the remaining 13 datasets. For each procedure, again with
the exception of the single best gene, we conducted univariate prescreening, choosing the
number of covariates to retain using 3-fold cross-validation.

5.1

Validation C-statistics

Figure 3 displays a meta-analysis of the C-statistics from 13 validation datasets, for weights
trained using the 452 samples of the TCGA dataset by each method. We used 100 bootstrap
samples of each validation datset to obtain 95% conﬁdence intervals. Uno et al. (2011)
proposed a perturbation-resampling approach to estimating conﬁdence intervals for the Cstatistic, but their method is only valid for risk score weights obtained by ﬁtting a Cox
model. Summary statistics were calculated by ﬁxed eﬀects meta-analysis with the metafor
R package (Viechtbauer, 2010).
Más-o-menos achieved the highest estimated C-statistics in eight out of the 13 datasets.
Lasso had the highest C-statistics in two datasets, as did marginal regression, and ridge
had the highest in one dataset. In addition, más-o-menos was about 10 times faster than
ridge and 30 times faster than lasso. As expected, lasso, ridge, marginal regression, and
más-o-menos outperformed the single best gene in most cases, which in turn outperformed
the random score.

5.2

Association with Batch Eﬀects

To help explain the good performance of más-o-menos in experimental data, we looked at
the inﬂuence of batch eﬀects (date of array hybridization) in the training TCGA dataset.
Table 3 provides one-way analysis of variance results for the risk scores of each method with
respect to batch in the TCGA training dataset. Each F-statistic, equal to the ratio of the
between-batch variance and the within-batch variance, quantiﬁes the amount of variability
15
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Lasso
0.57 [ 0.55 , 0.60 ]

Ridge
0.59 [ 0.57 , 0.61 ]

Marginal
0.60 [ 0.58 , 0.62 ]

Más−o−menos
0.62 [ 0.59 , 0.64 ]

Single Gene
0.51 [ 0.49 , 0.54 ]

Random
0.49 [ 0.47 , 0.52 ]

0.25

0.39

0.53

0.66

0.80

C−statistics
Figure 3: Validation C-statistics at 5 years using diﬀerent discrimination methods in ovarian
cancer datasets.
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Table 3: Analysis of Variance of risk scores for the predictions of each model with respect
to batches in the TCGA training dataset.
Method F-statistic (F13,437 ) p-value
Lasso
3.0
2.6 · 10−4
Ridge
3.4
4.5 · 10−5
Marginal
2.4
3.8 · 10−3
Más-o-menos
2.7
1.0 · 10−3
Single
3.9
5.4 · 10−6
Random
1.1
3.5 · 10−1
due to batch eﬀect. The top single gene was most strongly associated with batch, followed by
ridge and lasso. In contrast, marginal regression and más-o-menos were much more weakly
aﬀected. This is mostly likely a reﬂection of the heavily regularized nature of the marginal
and más-o-menos estimators, which are more biased than lasso and ridge in the training set
but can therefore deliver better results in the testing datasets.

6

Discussion

In this paper we study theoretical and practical properties of más-o-menos for prediction
from genomic data. This method has gained popularity in practice for its simplicity and
eﬀectiveness, but has little foundation in the statistical literature. We provide theoretical
arguments showing that más-o-menos can achieve good discrimination performance and is
more robust to overﬁtting relative to standard methods. These theoretical ﬁndings are supported empirically both by simulation studies and by an analysis of microarray data from 14
ovarian cancer microarray studies, where we found that más-o-menos oﬀered prediction performance comparable to or better than lasso and ridge regression, while providing signiﬁcant
advantages in speed and simplicity.
While we focused on microarray data and survival endpoints, más-o-menos can be applied
to outcomes of any type, using any regression model, and has precedent for application in diverse settings outside the ﬁeld of genomics (Wainer, 1976; Laughlin, 1978; Davis-Stober et al.,
2010; Lovie and Lovie, 1986). It is fast to implement, simple to understand, comparable in
17
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performance to far more complex methods, and is robust to variation in study-speciﬁc features. Más-o-menos should be useful for developing prediction models from high-dimensional
data in any situation where the covariates are suﬃciently correlated, and the true eﬀect is
roughly linear.
Batch eﬀects create study-speciﬁc measurement bias, and are widespread and often
unidentiﬁed in genomic data (Leek et al., 2010). Although certain batch-correction techniques have gained widespread use (Leek and Storey, 2007; Li and Rabinovic, 2007), these
have been motivated primarily by class comparison rather than class prediction. In a genomic prediction competition for several endpoints involving numerous research groups and
methods, batch correction was seen to provide no overall beneﬁt for validation accuracy
(MAQC Consortium, 2010). Rather, we propose that the degrading impact of batch eﬀects
on prediction models is best mitigated by methods that are relatively robust to over-ﬁtting
and to batch eﬀects. Más-o-menos and marginal regression risk scores were less associated
with batch in the TCGA training dataset than lasso and ridge regression, which were in turn
less associated than the single gene with strongest survival association (Table 3). The high
correlation between the best single gene with training set batch eﬀects, in contrast to the
relative insensitivity of más-o-menos to batch eﬀects, provides a likely explanation for the
superior prediction performance of más-o-menos across 13 independent validation datasets.
We also compared más-o-menos to marginal regression, which is equally fast and nearly
as simple. In our simulations in Section 4, diﬀerences between the two methods were not
pronounced, but más-o-menos achieved higher C-statistics than marginal regression on nearly
all of the ovarian cancer validation datasets. This is likely due to the lower variability of
más-o-menos, as discussed in Section 3.2, making it less likely to be aﬀected by study-speciﬁc
diﬀerences between training and test datasets.
We preceded each method with univariate feature selection. We performed additional
simulations, not reported here in detail, indicating that feature selection slightly improved
the performance of más-o-menos, as suggested by Section 3.2. It is well-known that univari-
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ate feature selection has drawbacks when important and unimportant covariates are highly
correlated. More complicated techniques such as iterative screening (Fan and Lv, 2008), a
type of stepwise variable selection, might improve the performance of the subsequent más-omenos procedure. On the other hand, these techniques are more diﬃcult to implement, their
theoretical properties are not well-understood, and they may not improve the ﬁnal results
by much, as our work indicates that univariate feature selection already performs well in
practice. We hope this work will help shift the emphasis of ongoing prediction modeling
eﬀorts in genomics from the development of complex models to the more important issues
of study design, model interpretation, and independent validation.
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Réme, T., Hose, D., Theillet, C., and Klein, B. (2013). Modeling Risk Stratiﬁcation in
Human Cancer. Bioinformatics (Oxford, England) pages 1–9.
Shaughnessy, J., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart,
J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007). A validated gene
23
Hosted by The Berkeley Electronic Press

expression model of high-risk multiple myeloma is deﬁned by deregulated expression of
genes mapping to chromosome 1. Blood 109, 2276–2284.
Struthers, C. and Kalbﬂeisch, J. (1986). Misspeciﬁed proportional hazard models. Biometrika
73, 363–369.
Tibshirani, R. J. (1996). Regression shrinkage and selection via the lasso. Journal of the
Royal Statistical Society, Ser. B 58, 267–288.
Tibshirani, R. J. (1997). The lasso method for variable selection in the Cox model. Statistics
in Medicine 16, 385–395.
Tothill, R., Tinker, A., George, J., Brown, R., Fox, S., Lade, S., Johnson, D., Trivett, M.,
Etemadmoghadam, D., Locandro, B., et al. (2008). Novel molecular subtypes of serous
and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research 14,
5198–5208.
Uno, H., Cai, T., Pencina, M. J., D’Agostino, R. B., and Wei, L. J. (2011). On the C-statistics
for evaluating overall adequacy of risk prediction procedures with censored survival data.
Statistics in Medicine 30, 1105–1117.
Uno, H., Tian, L., Cai, T., Kohane, I., and Wei, L. (2009). Comparing risk scoring systems
beyond the ROC paradigm in survival analysis.
van Noort, V., Snel, B., Huynen, M. A., et al. (2003). Predicting gene function by conserved
co-expression. TRENDS in Genetics 19, 238–242.
Verhaak, R. and Tamayo, P. (2013). Prognostically relevant gene signatures of high-grade
serous ovarian carcinoma. The Journal of Clinical Investigation pages 1–9.
Verweij, P. and Van Houwelingen, H. (1994). Penalized likelihood in cox regression. Statistics
in Medicine 13, 2427–2436.

24
http://biostats.bepress.com/harvardbiostat/paper158

Viechtbauer, W. (2010). Conducting meta-analyses in r with the metafor package. Journal
of Statistical Software 36, 1–48.
Wainer, H. (1976). Estimating coeﬃcients in linear models: it don’t make no nevermind.
Psychological Bulletin 83, 213–217.
Yoshihara, K., Tajima, A., Yahata, T., Kodama, S., Fujiwara, H., Suzuki, M., Onishi, Y.,
Hatae, M., Sueyoshi, K., Fujiwara, H., et al. (2010). Gene expression proﬁle for predicting
survival in advanced-stage serous ovarian cancer across two independent datasets. PloS
One 5, e9615.
Yoshihara, K., Tsunoda, T., Shigemizu, D., Fujiwara, H., Hatae, M., Fujiwara, H., Masuzaki,
H., Katabuchi, H., Kawakami, Y., Okamoto, A., et al. (2012). High-risk ovarian cancer
based on 126-gene expression signature Is uniquely characterized by downregulation of
antigen presentation pathway. Clinical Cancer Research 18, 1374–1385.
Zhao, S. D. and Li, Y. (2012). Principled sure independence screening for Cox models with
ultra-high-dimensional covariates. Journal of Multivariate Analysis 105, 397–411.

25
Hosted by The Berkeley Electronic Press

